These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 37433926)

  • 1. From mucosal infection to successful cancer immunotherapy.
    Goubet AG; Rouanne M; Derosa L; Kroemer G; Zitvogel L
    Nat Rev Urol; 2023 Nov; 20(11):682-700. PubMed ID: 37433926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.
    Wu Y; Enting D; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2015 May; 15(5):509-23. PubMed ID: 25882710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
    Semeniuk-Wojtaś A; Poddębniak-Strama K; Modzelewska M; Baryła M; Dziąg-Dudek E; Syryło T; Górnicka B; Jakieła A; Stec R
    Cancer Immunol Immunother; 2023 Jul; 72(7):1971-1989. PubMed ID: 36928373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
    Chung R; McKiernan J; Arpaia N; Marabelle A; Rouanne M
    Eur J Cancer; 2023 Jul; 187():58-64. PubMed ID: 37116288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.
    van Puffelen JH; Keating ST; Oosterwijk E; van der Heijden AG; Netea MG; Joosten LAB; Vermeulen SH
    Nat Rev Urol; 2020 Sep; 17(9):513-525. PubMed ID: 32678343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of Bladder Volume after BCG Immunotherapy.
    Yang C; Lv Z; Li Y
    Urol Int; 2021; 105(1-2):155-158. PubMed ID: 32882690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.
    Lima L; Severino PF; Silva M; Miranda A; Tavares A; Pereira S; Fernandes E; Cruz R; Amaro T; Reis CA; Dall'Olio F; Amado F; Videira PA; Santos L; Ferreira JA
    Br J Cancer; 2013 Oct; 109(8):2106-14. PubMed ID: 24064971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guérin immunotherapy.
    Subiela JD; Rodríguez Faba Ó; Aumatell J; Calderón J; Mercadé A; Balañà J; Esquinas C; Algaba F; Breda A; Palou J
    BJU Int; 2022 Apr; 129(4):542-550. PubMed ID: 34375494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of action of BCG therapy for bladder cancer--a current perspective.
    Redelman-Sidi G; Glickman MS; Bochner BH
    Nat Rev Urol; 2014 Mar; 11(3):153-62. PubMed ID: 24492433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.